Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease (2009)
- Authors:
- USP affiliated authors: FORLENZA, ORESTES VICENTE - FM ; GATTAZ, WAGNER FARID - FM
- Unidade: FM
- DOI: 10.1007/s00406-008-0828-5
- Subjects: DOENÇA DE ALZHEIMER (TERAPIA); LÍTIO (APLICAÇÕES TERAPÊUTICAS); PROTEÍNAS QUINASES (ANÁLISE;METABOLISMO)
- Language: Inglês
- Imprenta:
- Source:
- Título: European Archives of Psychiatry and Clinical Neurosciences
- ISSN: 0940-1334
- Volume/Número/Paginação/Ano: v. 259, n. 1, p. 16-22, 2009
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
MENDES, Camila Teixeira et al. Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease. European Archives of Psychiatry and Clinical Neurosciences, v. 259, n. 1, p. 16-22, 2009Tradução . . Disponível em: https://doi.org/10.1007/s00406-008-0828-5. Acesso em: 10 jan. 2026. -
APA
Mendes, C. T., Mury, F. B., Moreira, E. de S., Alberto, F. L., Forlenza, O. V., Dias Neto, E., & Gattaz, W. F. (2009). Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease. European Archives of Psychiatry and Clinical Neurosciences, 259( 1), 16-22. doi:10.1007/s00406-008-0828-5 -
NLM
Mendes CT, Mury FB, Moreira E de S, Alberto FL, Forlenza OV, Dias Neto E, Gattaz WF. Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease [Internet]. European Archives of Psychiatry and Clinical Neurosciences. 2009 ; 259( 1): 16-22.[citado 2026 jan. 10 ] Available from: https://doi.org/10.1007/s00406-008-0828-5 -
Vancouver
Mendes CT, Mury FB, Moreira E de S, Alberto FL, Forlenza OV, Dias Neto E, Gattaz WF. Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease [Internet]. European Archives of Psychiatry and Clinical Neurosciences. 2009 ; 259( 1): 16-22.[citado 2026 jan. 10 ] Available from: https://doi.org/10.1007/s00406-008-0828-5 - Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial
- Single-nucleotide polymorphisms of GSK3B, GAB2 and SORL1 in late-onset Alzheimer's disease: interactions with the APOE genotype
- Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression
- Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease
- Lithium efficacy in bipolar depression with flexible dosing: A six-week, open-label, proof-of-concept study
- Inhibition of phospolipase A2 modulates glycogen synthase activity and tau phosphorylation in primary cultures of cortical and hippocampal neurons
- Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer’s disease: a 4-year follow-up study
- Interleukin-1β Serum Levels is Increased in Antidepressant-Free Elderly Depressed Patients
- Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease
- Diagnosis and biomarkers of predementia in Alzheimer’s disease
Informações sobre o DOI: 10.1007/s00406-008-0828-5 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
